Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
about
Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation.Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical CancerThe emerging role of Twist proteins in hematopoietic cells and hematological malignanciesFER kinase activation of Stat3 is determined by the N-terminal sequenceSignal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesisSTAT6 expression in glioblastoma promotes invasive growthRequirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein.Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins.Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.STAT signaling in the pathogenesis and treatment of cancerImmunopathogenesis and therapy of cutaneous T cell lymphoma.Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteinsHuman and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV-2(pan-p)) transform T cells independently of Jak/STAT activation.STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytesStat3 activation is required for cellular transformation by v-src.Transforming growth factor alpha and mouse models of human breast cancer.Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.STAT signaling in the pathogenesis and treatment of leukemias.STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.STAT proteins: novel molecular targets for cancer drug discovery.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesInhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3.The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray.STAT proteins as novel targets for cancer drug discovery.Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines.Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cellsEPHA4 is overexpressed but not functionally active in Sézary syndrome.Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndromeStaphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphomaInterleukin-16 as a marker of Sézary syndrome onset and stage.Changing partners at the dance: Variations in STAT concentrations for shaping cytokine function and immune responses to viral infections.Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490.Elucidating the role of interleukin-17F in cutaneous T-cell lymphomaToll-like receptor agonists partially restore the production of pro-inflammatory cytokines and type I interferon in Sézary syndromeMalignant inflammation in cutaneous T-cell lymphoma-a hostile takeover
P2860
Q22253232-F9BC6588-3251-44C4-8A3B-455C901E9025Q26747008-43EF7BA4-F8E6-4AE1-B7CC-0294910BB514Q26822434-335C6DA0-DCCD-49A3-B448-A560CE680B97Q28139718-89DC76F1-7989-4C95-B25C-F514E44EDCCAQ30175784-1BF1518F-2ABE-4550-BC36-BB71CF136162Q30431789-BCB6C05D-5A05-4054-A48F-CE4078ABA7E7Q30453603-9A804EF3-10CC-4C8D-A969-49B351EE6594Q33509284-933C707E-D3E0-4C77-ADD6-A5EC659F036AQ33649606-26544C11-8B4C-419F-AEF0-A0F99F67C5B9Q33712802-E6B43958-FF27-46DB-9DE5-850746652572Q33726963-74EBF3CE-DA50-44A9-AF24-AA788C50A327Q33734222-00E1770E-4841-4975-9580-3120CE830308Q33782891-303BA2A8-CA01-47D2-A52A-A6ED272FFE4AQ33784496-C418CD51-0DE7-4A59-953B-2FDD5672DA82Q33786469-94CEE48D-CEA4-4797-9B6E-B1147A5D7191Q33860847-D908943D-123C-49B3-971A-D2C180C30E62Q33889476-89E293C6-41E7-4592-AF64-017D9CA29437Q33941357-1BAB0530-BE7D-4FAC-A6E6-83E86E72E18BQ34052726-0BFFC6F2-51E5-44BB-A2EF-463EE637B754Q34293579-EE5A3CDC-6A54-41B4-8A89-D4D7DF9CEC75Q35132241-2FA4E7BD-ED0F-45F3-B300-CA71B90C0B8CQ35626895-36A4B071-B58C-4994-A9D0-BCC9157D0BB1Q35680531-7BC91C67-A46D-45BC-ACB3-2F37F7DC9264Q35745808-C682535C-CDD8-4154-B6F1-6C2E0B2B2E0FQ35842022-9E7CA9AD-C64E-4C09-8323-C58F90C65284Q35911116-F19D0AC2-64EA-43F9-B19E-E007772A649FQ36048656-95303400-7BE0-4E91-8FA9-7811E90A444CQ36239779-7CAC720B-14C4-453C-A6B5-4E01342D1F0AQ36392832-31E8CBC2-E997-45A4-A96E-A54CC442750CQ36544714-062878FF-134D-4EF3-94C4-69DD4D5BF14FQ36626781-AF39B63C-F8B6-436E-AF63-EB476B2CA41EQ36675064-665D6CD9-B623-455E-98B9-A5E5F11FAF3FQ36890797-687694E1-0E1C-446B-BED4-07D516061E9FQ36895423-CD6049F0-DAB2-4967-B058-DC485C6D46C0Q36982497-0B4C5108-F001-443B-8D22-2FB98117506DQ37075919-8089FCC7-1AAB-4668-A27C-CF0A28F3830DQ37204775-DFA79365-DF4B-449C-8253-7CFAE31D1123Q37216178-A8399588-EE49-4F1B-BBE1-34426B959849Q37688819-FDA38E2A-367B-4CD5-8E84-996BCC37018CQ37723390-753AB5D7-C55A-489B-B715-B8C1BC0BF95E
P2860
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Activation of Jak/STAT protein ...... lymphoma and Sezary syndrome.
@en
Activation of Jak/STAT protein ...... lymphoma and Sezary syndrome.
@nl
type
label
Activation of Jak/STAT protein ...... lymphoma and Sezary syndrome.
@en
Activation of Jak/STAT protein ...... lymphoma and Sezary syndrome.
@nl
prefLabel
Activation of Jak/STAT protein ...... lymphoma and Sezary syndrome.
@en
Activation of Jak/STAT protein ...... lymphoma and Sezary syndrome.
@nl
P2093
P2860
P356
P1476
Activation of Jak/STAT protein ...... lymphoma and Sezary syndrome.
@en
P2093
E C Vonderheid
P C Nowell
P2860
P304
P356
10.1073/PNAS.93.17.9148
P407
P577
1996-08-01T00:00:00Z